欢迎访问云南西力生物技术股份有限公司!证券代码:871574
首页 成 果 源于西力产品的客户论文
Glycycoumarin Prevents Hepatic Steatosis through Activation of Adenosine 5-monophosphate (AMP)-activated Protein Kinase Signaling Pathway and Up-regulation of BTG1/Tob-1. J. Funct. Foods, 2017, 34: 277–286.
发布时间:2017-07-14 阅读数:1395 来源:J. Funct. Foods
分享到:

Abstract:

Glycycoumarin (GCM) is a representative of coumarin compounds isolated from licorice, a popular herbal plant which is widely used to treat various diseases including liver diseases. This study was designed to evaluate the protective effects of GCM on hepatic steatosis in the setting of non-alcoholic fatty liver disease using both cell culture model of OA (oleic acid) / PA (palmitate acid)-induced lipids accumulation and a murine model of hepatic steatosis induced by a methionine-choline-deficient (MCD) diet. Results showed that GCM was highly effective in removing lipids droplets in both in vitro and in vivo models. Mechanistically, we demonstrated that activation of adenosine 5'-monophosphate (AMP)-activated protein kinase (AMPK)-mediated lipophagy, lipogenesis inhibition and enhanced fatty acid oxidation contributed to the anti-lipogenic effect of GCM. Our findings support a possible usefulness of GCM as a novel agent to mitigate hepatic steatosis.


ewm.jpg 微信公众号
11.jpg 移动官网
特别声明:禁止在未经同意情况下转载本网站信息,BioBioPha品牌产品均由西力生物独家生产与销售,仅用于科学研究或企业研发!
版权所有 2019-2024 云南西力生物技术股份有限公司 BioBioPha 滇ICP备09000810号-1滇公安备案号 53019002000069号
技术支持:奥远科技

联系客服